|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 May 2001, Vol. 97, No. 9, pp. 2596-2603
HEMATOPOIESIS
Ionizing radiation sensitizes erythroleukemic cells
but not normal erythroblasts to tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective
up-regulation of TRAIL-R1
Roberta Di Pietro,
Paola Secchiero,
Rosalba Rana,
Davide Gibellini,
Giuseppe Visani,
Kristi Bemis,
Loris Zamai,
Sebastiano Miscia, and
Giorgio Zauli
From the Institute of Human Morphology, "G.
D'Annunzio" University of Chieti; the Department of Morphology and
Embryology, Human Anatomy Section, University of Ferrara; the
Department of Clinical and Experimental Medicine, Microbiology Section,
and "L.A. Seragnoli" Institute of Hematology, University of
Bologna; and the Institute of Morphological Sciences, University of
Urbino, Italy; and the Institute of Human Virology, University of
Maryland Biotechnology Institute, Baltimore.
Cytotoxic activity of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL/Apo-2 ligand), used alone or in
different combinations with either a low (1.5 Gy) or a high (15 Gy)
single dose of ionizing radiation (IR), was investigated on
erythroleukemic cells (K562, HEL, Friend, primary leukemic
erythroblasts) and on primary CD34+-derived normal
erythroblasts. Human recombinant TRAIL alone variably affected the
survival/growth of erythroleukemic cells; K562 cells were the most
sensitive. Moreover, all erythroleukemic cells were radio-resistant, as
demonstrated by the fact that cytotoxicity was evident only after
treatment with high-dose (15 Gy) IR. Remarkably, when IR and TRAIL were
used in combination, an additive effect was noticed in all
erythroleukemic cells. Augmentation of TRAIL-induced cell death by IR
was observed with both low and high IR doses and required the
sequential treatment of IR 3 to 6 hours before the addition of TRAIL.
Conversely, both TRAIL and IR showed a moderate cytotoxicity on primary
CD34+-derived normal erythroblasts when used alone, but
their combination did not show any additive effect. Moreover, the
cytotoxicity of IR plus TRAIL observed in erythroleukemic cells was
accompanied by the selective up-regulation of the surface expression of
TRAIL-R1 (DR4), and it was completely blocked by the z-Val-Ala-Asp
(OMe)-CH2 (z-VAD-fmk) caspase inhibitor. On the other hand,
the surface expression of TRAIL-R1 in CD34+-derived normal
erythroblasts was unaffected by IR, which induced the up-regulation of
the decoy TRAIL-R3. These data demonstrate that treatment with IR
provides an approach to selectively sensitize erythroleukemic cells,
but not normal erythroblasts, to TRAIL-induced apoptosis through the
functional up-regulation of TRAIL-R1.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. F. Tam, T.-L. Gu, J. Chen, B. H. Lee, L. Bullinger, S. Frohling, A. Wang, S. Monti, T. R. Golub, and D. G. Gilliland
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells
Blood,
September 1, 2008;
112(5):
1981 - 1992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Zamai, C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, L. Cocco, and M. Vitale
NK Cells and Cancer
J. Immunol.,
April 1, 2007;
178(7):
4011 - 4016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Briggs, K. E. Shults, L. A. Flye, S. A. McClintock-Treep, M. H. Jagasia, S. A. Goodman, F. I. Boulos, J. W. Jacobberger, G. T. Stelzer, and D. R. Head
Dysregulated Human Myeloid Nuclear Differentiation Antigen Expression in Myelodysplastic Syndromes: Evidence for a Role in Apoptosis.
Cancer Res.,
May 1, 2006;
66(9):
4645 - 4651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Zeng, A. Miyazato, G. Chen, S. Kajigaya, N. S. Young, and J. P. Maciejewski
Interferon-{gamma}-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles
Blood,
January 1, 2006;
107(1):
167 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. K. Rowinsky
Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activating Agents
J. Clin. Oncol.,
December 20, 2005;
23(36):
9394 - 9407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhang, R. M. Cheung, R. Komaki, B. Fang, and J. Y. Chang
Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non-Small Cell Lung Cancer
Clin. Cancer Res.,
September 15, 2005;
11(18):
6657 - 6668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Tourneur, S. Delluc, V. Levy, F. Valensi, I. Radford-Weiss, O. Legrand, J. Vargaftig, C. Boix, E. A. Macintyre, B. Varet, et al.
Absence or Low Expression of Fas-Associated Protein with Death Domain in Acute Myeloid Leukemia Cells Predicts Resistance to Chemotherapy and Poor Outcome
Cancer Res.,
November 1, 2004;
64(21):
8101 - 8108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Zauli, E. Rimondi, V. Nicolin, E. Melloni, C. Celeghini, and P. Secchiero
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF
Blood,
October 1, 2004;
104(7):
2044 - 2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Spierings, E. G. de Vries, E. Vellenga, F. A. van den Heuvel, J. J. Koornstra, J. Wesseling, H. Hollema, and S. de Jong
Tissue Distribution of the Death Ligand TRAIL and Its Receptors
J. Histochem. Cytochem.,
June 1, 2004;
52(6):
821 - 831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chawla-Sarkar, J. A. Bauer, J. A. Lupica, B. H. Morrison, Z. Tang, R. K. Oates, A. Almasan, J. A. DiDonato, E. C. Borden, and D. J. Lindner
Suppression of NF-{kappa}B Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL
J. Biol. Chem.,
October 10, 2003;
278(41):
39461 - 39469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Greil, G. Anether, K. Johrer, and I. Tinhofer
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
J. Leukoc. Biol.,
September 1, 2003;
74(3):
311 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. J. Spierings, E. G. E. de Vries, W. Timens, H. J. M. Groen, H. M. Boezen, and S. de Jong
Expression of TRAIL and TRAIL Death Receptors in Stage III Non-Small Cell Lung Cancer Tumors
Clin. Cancer Res.,
August 1, 2003;
9(9):
3397 - 3405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Hietakangas, M. Poukkula, K. M. Heiskanen, J. T. Karvinen, L. Sistonen, and J. E. Eriksson
Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP
Mol. Cell. Biol.,
February 15, 2003;
23(4):
1278 - 1291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Secchiero, A. Gonelli, P. Mirandola, E. Melloni, L. Zamai, C. Celeghini, D. Milani, and G. Zauli
Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway
Blood,
September 18, 2002;
100(7):
2421 - 2429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
